Published in J Virol on November 25, 2009
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol (2012) 1.36
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell (2013) 1.23
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol (2011) 1.19
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol (2012) 1.14
The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol (2010) 1.05
Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities. Front Microbiol (2011) 1.02
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol (2012) 0.99
APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum Immunol (2010) 0.92
Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One (2012) 0.92
Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. J Virol (2011) 0.91
IFN-α and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways. J Immunol (2012) 0.90
Structural insights for HIV-1 therapeutic strategies targeting Vif. Trends Biochem Sci (2014) 0.89
Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology (2013) 0.87
The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS One (2013) 0.86
A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. Virology (2014) 0.86
Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression. J Virol (2013) 0.85
Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J Mol Biol (2013) 0.84
Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif. J Virol (2014) 0.83
APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics (2015) 0.82
Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities. Retrovirology (2015) 0.80
Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors. Retrovirology (2016) 0.80
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. PLoS One (2014) 0.80
A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection. J Virol (2015) 0.80
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrob Agents Chemother (2015) 0.79
Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability. J Biol Chem (2015) 0.79
D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology (2013) 0.78
APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population. J Hum Genet (2015) 0.77
Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H. Virology (2013) 0.76
Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif. Cell Cycle (2015) 0.76
Long-term passage of Vif-null HIV-1 in CD4(+) T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance. Virology (2017) 0.75
Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C. J Virol (2016) 0.75
APOBEC3DE Inhibits LINE-1 Retrotransposition by Interacting with ORF1p and Influencing LINE Reverse Transcriptase Activity. PLoS One (2016) 0.75
The structural interface between HIV-1 Vif and human APOBEC3H. J Virol (2016) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
Intrinsic immunity: a front-line defense against viral attack. Nat Immunol (2004) 4.95
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 3.76
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol (2006) 3.57
Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol (2004) 3.57
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
Automated server predictions in CASP7. Proteins (2007) 3.40
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev (2004) 3.28
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
The AID/APOBEC family of nucleic acid mutators. Genome Biol (2008) 3.25
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Retrovirus restriction factors. Mol Cell (2004) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology (2005) 2.84
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem (2004) 2.79
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol (2006) 2.40
Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature (2008) 2.36
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28
The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature (2006) 2.28
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol (2005) 2.17
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem (2006) 2.06
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol (2006) 1.98
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology (2006) 1.86
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83
APOBEC3G targets specific virus species. J Virol (2004) 1.78
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol (2006) 1.69
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J (2006) 1.64
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol (2007) 1.53
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science (2004) 1.41
Editing at the crossroad of innate and adaptive immunity. Science (2005) 1.40
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology (2007) 1.35
Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol (2007) 1.27
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect (2008) 1.05
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr Opin HIV AIDS (2006) 0.96
APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem (2005) 0.93
RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine (2008) 0.90
Human APOBEC3G incorporation into murine leukemia virus particles. Virology (2005) 0.89
Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell (2009) 11.36
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
The carbon balance of terrestrial ecosystems in China. Nature (2009) 6.84
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell (2009) 5.49
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Aging, progenitor cell exhaustion, and atherosclerosis. Circulation (2003) 5.19
Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res (2009) 4.49
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab (2007) 4.16
Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty (2008) 4.11
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med (2007) 3.61
Mobile interspersed repeats are major structural variants in the human genome. Cell (2010) 3.60
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet (2012) 3.34
Design of stable alpha-helical arrays from an idealized TPR motif. Structure (2003) 3.17
Modeling quantitative trait Loci and interpretation of models. Genetics (2005) 3.15
Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat Immunol (2008) 3.05
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell (2008) 2.69
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
Cell wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin stimulon. Mol Microbiol (2003) 2.62
Global analysis of the Bacillus subtilis Fur regulon and the iron starvation stimulon. Mol Microbiol (2002) 2.55
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
Structure of a prokaryotic virtual proton pump at 3.2 A resolution. Nature (2009) 2.53
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. Mol Cell (2010) 2.40
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Antibiotics that inhibit cell wall biosynthesis induce expression of the Bacillus subtilis sigma(W) and sigma(M) regulons. Mol Microbiol (2002) 2.32
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature (2011) 2.26
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19
Ascaris suum draft genome. Nature (2011) 2.16
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Evaluation of terrestrial carbon cycle models for their response to climate variability and to CO2 trends. Glob Chang Biol (2013) 2.13
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci (2011) 2.11
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med (2011) 2.08
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
Exploring the engine of anthropogenic iron cycles. Proc Natl Acad Sci U S A (2006) 2.03
Early millet use in northern China. Proc Natl Acad Sci U S A (2012) 2.01
Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development (2006) 2.01
Metabolic syndrome is associated with better nutritional status, but not with cardiovascular disease or all-cause mortality in patients on haemodialysis. Arch Cardiovasc Dis (2012) 1.99
Abdominal Paracentesis Drainage Does Not Increase Infection in Severe Acute Pancreatitis: A Prospective Study. J Clin Gastroenterol (2015) 1.97
Esrrb activates Oct4 transcription and sustains self-renewal and pluripotency in embryonic stem cells. J Biol Chem (2008) 1.95
PMRD: plant microRNA database. Nucleic Acids Res (2009) 1.94
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One (2010) 1.94
Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine (2010) 1.92
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol (2008) 1.90
Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood (2012) 1.86
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology (2006) 1.86
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: a proteomic analysis. Proc Natl Acad Sci U S A (2004) 1.85
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood (2013) 1.84
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat (2009) 1.83
Ethnic differences in out-of-hospital fatal pulmonary embolism. Circulation (2011) 1.82
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood (2009) 1.81
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene (2004) 1.77
Crystal structure of a bulged RNA tetraplex at 1.1 a resolution: implications for a novel binding site in RNA tetraplex. Structure (2003) 1.77
DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol (2007) 1.77
First snapshots of the HIV-1 RNA structure in infected cells and in virions. J Biol Chem (2004) 1.76
Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J (2008) 1.76
High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med (2015) 1.74
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Structure of a synaptic gammadelta resolvase tetramer covalently linked to two cleaved DNAs. Science (2005) 1.73
The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int (2011) 1.72
Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model. Proc Natl Acad Sci U S A (2012) 1.71
The crystal structure of yeast fatty acid synthase, a cellular machine with eight active sites working together. Cell (2007) 1.70
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol (2003) 1.70
The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature (2012) 1.70
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant (2010) 1.69
The draft genome of the fast-growing non-timber forest species moso bamboo (Phyllostachys heterocycla). Nat Genet (2013) 1.68
Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health Policy Plan (2008) 1.68
Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature (2011) 1.67
Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region. Biochem J (2010) 1.66
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J (2006) 1.64
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Chemical contribution to surface-enhanced Raman scattering. Phys Rev Lett (2006) 1.63